European vs 2015-World Health Organization clinical molecular and pathological classification of myeloproliferative neoplasms

Figure 14 Genotype of individual BFU-E in polycythemia vera and essential thrombocythemia with granulocytes heterozygous for the JAK2^V617F mutation (less than 50% JAK2^V617F mutation load) show that polycythemia vera patients are heterozygous/homozygous and essential thrombocythemia patients heterozygous for the JAK2^V617F somatic mutation. ET: Essential thrombocythemia; PV: Polycythemia vera; WT: Wild type; BFU-e: Burst forming units erythropoiesis.